Literature DB >> 8436659

Necrosis of the hand after extravasation of intravenously administered phenytoin.

A G Hayes1, T M Chesney.   

Abstract

Extravascular escape of intravenously administered phenytoin can result in serious local soft tissue complications. Injury can range from simple phlebitis to chemical cellulitis or, in extreme cases, frank tissue necrosis that necessitates amputation. The histopathologic findings include extensive necrosis and sloughing of epidermis, widespread necrosis of dermis, subcutaneous tissue, muscles and nerves, and extensive thrombotic occlusion of vessel lumens. Results of elastic tissue stains reveal that the thrombosed vessels are exclusively veins and venules. Vascular fibrinoid necrosis, leukocytoclasis, and true inflammatory vasculitis are not features. This is the first detailed report of the histopathologic alterations associated with this therapeutic misadventure.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8436659     DOI: 10.1016/0190-9622(93)70055-x

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  4 in total

Review 1.  Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.

Authors:  J C DeToledo; R E Ramsay
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

Review 2.  Purple Glove Syndrome after Phenytoin or Fosphenytoin Administration: Review of Reported Cases and Recommendations for Prevention.

Authors:  Lyudmila A Garbovsky; Byron C Drumheller; Jeanmarie Perrone
Journal:  J Med Toxicol       Date:  2015-12

Review 3.  [Refractory status epilepticus: diagnosis, therapy, course, and prognosis].

Authors:  F Bösebeck; G Möddel; K Anneken; M Fischera; S Evers; E B Ringelstein; C Kellinghaus
Journal:  Nervenarzt       Date:  2006-10       Impact factor: 1.214

4.  Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers.

Authors:  Yushi Inoue; Naotaka Usui; Tadayuki Hiroki; Kenji Shimizu; Susumu Kobayashi; Shigeki Shimasaki
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-09-12       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.